## CPTC-CD274-1 (CAB079981)

#### Uniprot ID: Q9NZQ7

Protein name: PD1L1\_HUMAN

#### Full name: Programmed cell death 1 ligand 1

Tissue specificity: Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.

**Function**: Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813417, PubMed:28813417, PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

#### Subcellular location:

#### Unnamed:

Cell membrane (*experimental evidence*) (Topo: Single-pass type I membrane protein (*match to sequence model*)) Early endosome membrane (*experimental evidence*) (Topo: Single-pass type I membrane protein (*match to sequence model*))

Recycling endosome membrane (experimental evidence) (Topo: Single-pass type I membrane protein (match to sequence model))

NOTE: Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation.

#### Isoform 1:

Cell membrane (*experimental evidence*) (Topo: Single-pass type I membrane protein (*match to sequence model*)) **Isoform 2**:

Endomembrane system (*experimental evidence*) (Topo: Single-pass type I membrane protein (*match to sequence model*)) **Protein existence**: Experimental evidence at protein level

#### Comment:

## Immunohistochemistry



IHC protocol:	HIER pH6, Dilution 1:250	
IHC test staining:	Weak to moderate cytoplasmic positivity in gastrointestinal tract and pancreas.	
Literature conformance:	Not consistent with gene/protein characterization data	
Literature significance:		
RNA consistency:	Not consistent with RNA expression data	
IHC Sibling similarity:	Other antibody shows dissimilar IHC staining pattern	
IHC fail comment:	ANTIBODY FAILED: Improbable histological location,Not consistent with RNA	

### Immunofluorescence



IF Overlay:	antibody (green), anti-tubuline (red) and DAPI (blue)	
IF main location:		
IF additional location:		
IF Antibody score:	Failed IF	
IF in HEL:	Negative	
IF in U-2 OS:	Negative	

# Western blot

WB Size markers (kDa):	250, 130, 100, 70, 55, 35, 25, 15, 10
WB Lanes:	Marker (1), RT4 (2), U-251 MG (3), Plasma (4), Liver (5), Tonsil (6)
WB Target weight (kDa):	20, 33
WB Validation:	Uncertain (Single band differing more than +/-20% from predicted size in kDa and not supported by experimental and/or bioinformatic data.)